Virtual event on
The event will feature a presentation from KOL Ben Philpot, Ph.D., Associate Director of the UNC Neuroscience Center at UNC-Chapel Hill, who will discuss the gene replacement approach to treating patients with Angelman syndrome, a genetic condition that affects the nervous system and causes severe physical and learning disabilities.
The event will also feature presentations from:
Kimberly Goodspeed, M.D., Assistant Professor in the Departments of Pediatrics, Neurology, and Psychology at UT Southwestern, who will provide an overview of Angelman syndrome
Allyson Berent DVM, Dipl. ACVIM, Chief Science Officer for the
Foundation for Angelman Therapeutics, Director of the Angelman Syndrome Biomarker and Outcome Measure Consortiumand Co-Director of the International Angelman Syndrome Research Council, who will discuss the natural history of the disease and the burden of disease as well as provide a patient and caregiver perspective
Ryan Butler, Ph.D., Assistant Professor in the Department of Psychiatry and Pediatricsat UT Southwestern, who will discuss the vectorized knockdown of UBE3A-ATS approach to treating Angelman syndrome
Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of R&D of Taysha, who will review the clinical development strategy for the treatment of Angelman syndrome
To register for the investor day, please click here. A live video webcast will be available in the "Events & Media" section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.
SVP, Corporate Communications and Investor Relations